نتائج البحث 71-80 من 7596 لعملية البحث عن Residual
Rochester, Minn. The purpose of this study is to compare whether minimal residual disease (MRD) flow cytometric assay is not affected by different ...
placebo in combination with ado-trastuzumab emtansine (TTT-DM1) in patients with stage II-III HER2+ breast cancer with residual disease post-neoadjuvant ...
... residual colon/rectum/pouch as the primary disease site. Analyses of Metabolic Agents Following Brain Radiation. Rochester, Minn. The purpose of this study ...
This drug combination is still experimental and is not approved by the FDA. Discontinuation of pirtobrutinib and venetoclax based on minimal residual disease ( ...
Collection of tissue and blood from patients with residual disease after neoadjuvant systemic therapy for breast cancer. We hope to use these samples to ...
... residual colon/rectum/pouch as the primary disease site. Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor ...
... residual colon/rectum/pouch as the primary disease site. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib to To Treat ...
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.